Similar companies
Income Statement (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 1.24B | 867.2% |
| Gross Profit | 1.07B | 1447% |
| Cost of Revenue | 179M | 199.2% |
| Operating expense | 1.06B | 2% |
| Net Income | 198M | 124.5% |
| EBITDA | 211M | 128.2% |
Balance Sheet (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 22.4B | 0.7% |
| Total Liabilities | 3.29B | 3.8% |
| Total Equity | 19.1B | 0.2% |
| Shares Outstanding | 225M | 6.4% |
Cash Flow (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -639M | 139.3% |
| Cash from financing | -7.9M | 65.5% |
Financial Highlights for BioNTech in Q3 '24
BioNTech reported a revenue of 1.24B, which is a 867.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.07B, marking a 1447% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 179M, a 199.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.06B, showing a 2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 198M, showing a 124.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 211M, showing a 128.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for BioNTech with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
